Meet us at ISPOR 2026
May 17 - 20 | Philadelphia, PA
Generate outcomes and cost-effectiveness evidence to accelerate regulatory approval and reimbursement
Reach out and we’ll schedule a meeting.
Join the conversation on the future of real-world evidence
At ISPOR 2026, see how Truveta helps HEOR teams generate timely, decision-ready evidence from linked, longitudinal real-world data. Truveta Data includes de-identified, daily refreshed EHR data for more than 130 million patients—including clinical notes and imaging—linked with closed claims, mortality, and social drivers of health to enable longitudinal research across the full patient journey. Explore how researchers are using Truveta to study outcomes, treatment patterns, access, and cost-relevant questions with greater speed and clinical depth.
Explore our latest research
Dive into findings on maternal health, cardiovascular disease, mental health, and more.
Minutes, not months: AI-enabled insights to drive evidence strategy
May 18 | 3:15 - 3:45pm
Modern real-world data can surface insights and opportunities far earlier than traditional trials and registries, yet evidence strategy is often shaped by answers that arrive months, or even years, late. As a result, HEOR teams may commit to post-launch evidence plans before emerging patterns in real-world practice are fully understood.
Using artificial intelligence (AI), HEOR teams can generate real-time answers in minutes, not months, from longitudinal, omnimodal real-world data. These immediate answers enable teams to explore, refine, and prioritize evidence that improve patient outcomes, accelerate regulatory approvals, and secure market access.
Join us to discover how real-time, AI-enabled answers compress evidence strategy timelines, reduce exploratory dead ends, and ensure that downstream evidence generation is focused on the questions that matter most right now.
Join us to discover how Truveta Data is delivering insights far ahead of postmarket trial data. We’ll explore findings from published studies using Truveta Data to examine GLP-1 utilization trends, comparative effectiveness for weight loss, access barriers, factors influencing discontinuation and reinitiation, and more.
Johnathan Lancaster, MD, PhD
President & Chief Scientific Officer
Michael Simonov, MD
Senior Vice President, Product
Research posters
Clinical and care delivery research
 |
Trends in the guideline-directed medical therapy among patients with heart failure with reduced ejection fraction May 18 | 10:30am – 1:30pm Rapid initiation of all four recommended heart failure therapies remains uncommon in real-world care, despite improvement over time. Using EHR data, Truveta Research and collaborators found progress from 2020 to 2024 was driven largely by SGLT2 inhibitors, and that faster treatment initiation was more likely when care began in the hospital. These findings highlight actionable opportunities to improve inpatient starts, discharge processes, and medication follow-through. Join us to learn how faster treatment initiation can help close care gaps. |
 |
Temporal trends and determinants of aortic valve replacement in patients with asymptomatic severe aortic stenosis May 20 | 9:00 – 11:30am Aortic valve replacement became markedly more common among patients with asymptomatic severe aortic stenosis from 2017 to 2024, even before new trial evidence supported earlier intervention. Truveta Research and collaborators found important differences in who received treatment, highlighting how disease presentation and patient characteristics may influence access to valve replacement before symptoms begin. Join us to see how earlier intervention is evolving for patients with severe aortic stenosis and where treatment variation remains. |
Maternal and adolescent health research
 |
Exploring gestational weight change among mothers and associated newborn weight May 18 | 4:00 – 7:00pm How much weight mothers gain during pregnancy can affect newborn birthweight. Using EHR data, Truveta Research examined weight change during pregnancy and its association with newborn birthweight. The study found that greater gestational weight gain was associated with higher birthweight, while lower weight gain and maternal weight loss were associated with lower birthweight. Join us to explorehow real-world evidence can help improve understanding of maternal and newborn health. |
 |
Associations of gestational diabetes treatment with maternal weight change and newborn birthweight May 19 | 10:30am – 1:30pm How do gestational diabetes treatments relate to maternal and newborn outcomes in real-world practice? Using linked EHR and closed claims data, Truveta Research found that nutrition counseling was associated with lower maternal weight gain, while metformin use was associated with lower risk of large-for-gestational-age birthweight. Join us to see how real-world data can help evaluate the impact of gestational diabetes treatment on maternal and newborn outcomes. |
 |
Sleep disorder diagnosis in adolescence and subsequent mental health diagnoses – A retrospective cohort study May 19 | 10:30am – 1:30pm Adolescents diagnosed with a sleep disorder had higher odds of receiving a mental health diagnosis within one year. Using EHR data, Truveta Research found increased likelihood of subsequent anxiety, depression, and ADHD diagnoses, pointing to sleep disorders as a potential early marker of broader mental health risk in adolescence. Join us to learn how sleep disorder diagnosis may help identify adolescents at higher risk for subsequent mental health conditions. |
AI innovation and data science
 |
Mapping oncology patient journeys using a data-driven Markov transition matrix May 18 | 4:00 – 7:00pm Cancer journeys are rarely linear, and patients often move through overlapping phases of disease, comorbidity, and symptom burden over time. Using large-scale EHR data, Truveta showed that a data-driven Markov transition approach can characterize patient journeys, capture clinically meaningful comorbidity patterns, and inform the parameterization of Markov models in health outcomes research. Join us to examine how longitudinal patient journey data can strengthen outcomes modeling in oncology. |
 |
Zero-shot lung cancer risk prediction from longitudinal electronic health records with chain-of-agents framework May 18 | 4:00 – 7:00pm Identifying patients at elevated risk for lung cancer remains a key challenge for early detection. In this work, Truveta applied a large language model–based chain-of-agents framework to raw longitudinal EHR data and showed it could estimate 1-year lung cancer risk with performance comparable to traditional machine learning models, while reducing the need for extensive data preprocessing and task-specific training. Join us to discover how new AI methods could support more scalable approaches to lung cancer risk assessment. |
 |
Can a generative patient journey foundation model alleviate the burden of cancer screening? May 19 | 4:00 – 7:00pm Cancer screening can be costly and resource-intensive, especially when many tests do not lead to a cancer diagnosis. Using de-identified EHR data, Truveta found that a generative patient journey model showed strong performance in predicting negative cancer outcomes across four cancer types, pointing to the potential for AI to complement clinical assessment and inform more targeted screening strategies. Join us to examine how predictive modeling may help reduce unnecessary screening burden. |
 |
Patient journey foundational model for scalable imputation of missing units and measurement (UoM) in electronic health records data May 20 | 9:00 – 11:30am Missing units of measurement can limit the usability of EHR data for research and analysis. Using a transformer-based patient journey model, Truveta found it was possible to impute missing units of measurement with high accuracy, demonstrating a scalable approach to improving data completeness and reducing manual data cleaning. Join us to discover how AI can help strengthen EHR data quality for research and downstream applications. |
Visit us at booth #505
See how life sciences companies and governmental organizations are using Truveta as their trusted source of patient data to generate timely evidence at booth #505.
Talk to our experts about what makes Truveta Data unique, how researchers are using our dataset, and how we can accelerate your organization’s research.
We’ll be serving drinks at the booth on May 18 at 5:00pm. Come by and have one on us.
